文献速递垂体与肾上腺疾病

每日一次口服Paltusotine治疗肢端肥大症的长期安全性与疗效:ACROBAT Advance开放标签扩展至4年

Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years.
PubMed 文献 · J Clin Endocrinol Metab · 2026-06-26

ACROBAT Advance开放标签扩展研究评估每日一次口服Paltusotine在既往接受注射生长抑素受体配体治疗的肢端肥大症患者中的长期疗效与安全性。43例患者入组,中位IGF-I水平从基线1.15×ULN降至第207周1.01×ULN,生长激素、症状和垂体瘤大小保持稳定,耐受性良好,仅2例(4.7%)因不良事件停药。

要点

  • Paltusotine是首个获批的每日一次口服选择性生长抑素2受体激动剂。
  • 长期治疗至4年可维持IGF-I、生长激素、症状及垂体瘤大小的稳定控制。
  • 耐受性良好,因不良事件停药率低(2/43,4.7%)。

核心结论

  • 每日一次口服Paltusotine治疗耐受性良好,并实现长达4年的长期疾病控制,包括生化、症状和垂体瘤稳定性。

研究设计与样本

  • ACROBAT Advance是一项正在进行的开放标签扩展研究,报告至第4年的中期结果。
  • 入组患者已完成2期母研究ACROBAT Edge或ACROBAT Evolve,共43例(占符合条件患者的88%)入组。
  • Paltusotine最大剂量最初为40 mg,第3年片剂上市后增至60 mg;允许根据临床需要联用卡麦角林或培维索孟。

主要发现

  • 中位(四分位距)IGF-I水平:母研究基线(n=43)为1.15×ULN(0.84,1.46),Advance第3周(n=43)为1.17×ULN(0.98,1.54),Advance第207周(n=20)为1.01×ULN(0.83,1.13)。
  • 生长激素水平、肢端肥大症症状和垂体瘤大小保持稳定。
  • Paltusotine耐受性良好,未观察到意外安全性发现。
  • 截至分析时,8例(18.6%)患者中止研究,其中2例(4.7%)因不良事件中止。

临床怎么用

  • 对于既往接受注射生长抑素受体配体治疗的肢端肥大症患者,每日一次口服Paltusotine可作为一种长期治疗选择,维持生化、症状和肿瘤控制。

局限性

  • 开放标签扩展研究,无对照且样本量有限(43例入组,第207周仅20例有数据),可能影响结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Paltusotine is the first non-peptide selective somatostatin 2 receptor agonist approved as once-daily oral treatment for acromegaly. OBJECTIVE: To evaluate long-term treatment with paltusotine in patients with acromegaly previously on an injected somatostatin receptor ligand (SRL)-based regimen. METHODS: ACROBAT Advance is an ongoing open-label extension (OLE) study. Interim results (up to year 4) are reported. Enrolled patients had completed a phase 2 parent study: ACROBAT Edge (baseline insulin-like growth factor I [IGF-I] > 1× upper limit of normal [ULN] on injected octreotide or lanreotide ± cabergoline, or baseline IGF-I ≤ 1×ULN with combination therapy or pasireotide) or ACROBAT Evolve (baseline IGF-I ≤ 1×ULN on injected SRL monotherapy). Maximum paltusotine dose was initially 40 mg, then 60 mg, when a tablet formulation became available in year 3. Adjunctive treatment with cabergoline or pegvisomant was allowed as clinically indicated. RESULTS: Forty-three patients (88% of eligible patients from ACROBAT Edge and Evolve) enrolled in the OLE. Median (interquartile range) IGF-I levels were: 1.15×ULN (0.84, 1.46) at parent study baseline (n = 43), 1.17×ULN (0.98, 1.54) at Advance week 3 (n = 43), and 1.01×ULN (0.83, 1.13) at Advance week 207 (n = 20). Growth hormone levels, acromegaly symptoms, and pituitary tumor size remained stable. Paltusotine was well tolerated, with no unexpected safety findings observed. As of this analysis, 8 (18.6%) patients had discontinued from the study, including 2 (4.7%) due to adverse events. CONCLUSIONS: Once-daily oral paltusotine treatment was well tolerated and resulted in long-term disease control, including biochemical, symptom, and pituitary tumor stability, for up to 4 years.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gadelha MR, Gordon MB, Doknic M, et al. Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years. J Clin Endocrinol Metab. 2026. PMID: 42359578. doi:10.1210/clinem/dgag254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。